Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-α with melphalan and prednisone (MP) and interferon-α (IFN-α) in patients with good-prognosis multiple myeloma: a prospective randomized study
- 1 January 2001
- journal article
- clinical trial
- Published by Wiley in European Journal of Haematology
- Vol. 66 (1) , 18-23
- https://doi.org/10.1034/j.1600-0609.2001.00285.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Should alpha-interferon be included as standard treatment in multiple myeloma?European Journal Of Cancer, 1998
- Effect of interferon on the health‐related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan–prednisone to melphalan–prednisone + α‐interferonBritish Journal of Haematology, 1996
- Interferon-α 2b Added to Melphalan-Prednisone for Initial and Maintenance Therapy in Multiple MyelomaAnnals of Internal Medicine, 1996
- Complete remission induction with combined VBMCP chemotherapy and interferon (rIFNα2b) in patients with multiple myelomaLeukemia & Lymphoma, 1996
- Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.Journal of Clinical Oncology, 1992
- Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group StudyLeukemia & Lymphoma, 1990
- Multiple MyelomaMedical Clinics of North America, 1984
- INTERFERON THERAPY IN MYELOMATOSISThe Lancet, 1979
- High Speed Scintillation AutoradiographyScience, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958